Pharmaceutical News and Articles

Boston Scientific Announces Japanese Approval for the Taxus Express2 Stent System

NATICK, Mass., April 03, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation announced today that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Japan. The Company plans to launch the product after reimbursement approval is granted.

"The approval of the TAXUS Express2 stent is an important event for the treatment of cardiovascular disease in Japan," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "We are pleased to provide Japanese physicians with this proven technology, which will help improve the quality of life for so many patients."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

    CONTACT:  Paul Donovan

              508-650-8541 (office)

              508-667-5165 (mobile)

              Media Relations

              Boston Scientific Corporation


              Dan Brennan

              508-650-8538 (office)

              617-459-2703 (mobile)

              Investor Relations

              Boston Scientific Corporation


Boston Scientific Corporation

CONTACT: Paul Donovan, Media Relations, +1-508-650-8541, mobile:+1-508-667-5165, or Dan Brennan, Investor Relations, +1-508-650-8538,mobile: +1-617-459-2703, both of Boston Scientific Corporation

Web site: http://www.bostonscientific.com/

Ticker Symbol: (NYSE:BSX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Latest Pharma Industry News...

Pharma Industry News Archive

2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

MedNotes
Advertisement

(web4)